Cargando…

Multivariable risk-based patient selection for prostate biopsy in a primary health care setting: referral rate and biopsy results from a urology outpatient clinic

BACKGROUND: According to their guidelines, Dutch general practitioners (GPs) refer men with prostate-specific antigen (PSA) level ≥3.0 ng/mL to the urologist for risk-based patient selection for prostate biopsy using the Rotterdam Prostate Cancer Risk Calculator (RPCRC). Use of the RPCRC in primary...

Descripción completa

Detalles Bibliográficos
Autores principales:	Osses, Daniël F., Alberts, Arnout R., Bausch, Gonny C. F., Roobol, Monique J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861274/ https://www.ncbi.nlm.nih.gov/pubmed/29594017 http://dx.doi.org/10.21037/tau.2017.12.11

Ejemplares similares

Distribution of Prostate Imaging Reporting and Data System score and diagnostic accuracy of magnetic resonance imaging–targeted biopsy: comparison of an Asian and European cohort
por: Zhang, Kai, et al.
Publicado: (2019)

A Tool for Shared Decision Making on Referral for Prostate Biopsy in the Primary Care Setting: Integrating Risks of Cancer with Life Expectancy
por: Verbeek, Jan F.M., et al.
Publicado: (2019)

Prostate cancer upgrading with serial prostate magnetic resonance imaging and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary?
por: Osses, Daniël F., et al.
Publicado: (2020)

Multivariate risk prediction tools including MRI for individualized biopsy decision in prostate cancer diagnosis: current status and future directions
por: Schoots, Ivo G., et al.
Publicado: (2019)

Comparison of clinically significant prostate cancer detection by MRI cognitive biopsy and in-bore MRI-targeted biopsy for naïve biopsy patients
por: Zhang, Kai, et al.
Publicado: (2020)

Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies
por: Osses, Daniël F., et al.
Publicado: (2020)

Reducing prostate biopsies and magnetic resonance imaging with prostate cancer risk stratification
por: Davik, Petter, et al.
Publicado: (2022)

Head-to-head comparison of prostate cancer risk calculators predicting biopsy outcome
por: Pereira-Azevedo, Nuno, et al.
Publicado: (2018)

Reduction of MRI-targeted biopsies in men with low-risk prostate cancer on active surveillance by stratifying to PI-RADS and PSA-density, with different thresholds for significant disease
por: Schoots, Ivo G., et al.
Publicado: (2018)

Personalized Decision Making for Biopsies in Prostate Cancer Active Surveillance Programs
por: Tomer, Anirudh, et al.
Publicado: (2019)

Prediction Medicine: Biomarkers, Risk Calculators and Magnetic Resonance Imaging as Risk Stratification Tools in Prostate Cancer Diagnosis
por: Osses, Daniël F., et al.
Publicado: (2019)

Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting
por: White, Jay, et al.
Publicado: (2017)

Predicting Low-Risk Prostate Cancer from Transperineal Saturation Biopsies
por: van Leeuwen, Pim J., et al.
Publicado: (2016)

Reducing Biopsies and Magnetic Resonance Imaging Scans During the Diagnostic Pathway of Prostate Cancer: Applying the Rotterdam Prostate Cancer Risk Calculator to the PRECISION Trial Data
por: Remmers, Sebastiaan, et al.
Publicado: (2021)

Large and small cribriform architecture have similar adverse clinical outcome on prostate cancer biopsies
por: Rijstenberg, L Lucia, et al.
Publicado: (2022)

Prostate biopsy approach and complication rates
por: Mate, Kinga, et al.
Publicado: (2023)

Negative Biopsy after Referral for Biopsy-Proven Gastric Cancer
por: Tae, Chung Hyun, et al.
Publicado: (2016)

Multivariable Models Incorporating Multiparametric Magnetic Resonance Imaging Efficiently Predict Results of Prostate Biopsy and Reduce Unnecessary Biopsy
por: Yu, Shuanbao, et al.
Publicado: (2020)

Concordance of cribriform architecture in matched prostate cancer biopsy and radical prostatectomy specimens
por: Hollemans, Eva, et al.
Publicado: (2019)

Expert Involvement Predicts mHealth App Downloads: Multivariate Regression Analysis of Urology Apps
por: Pereira-Azevedo, Nuno, et al.
Publicado: (2016)

Personalised biopsy schedules based on risk of Gleason upgrading for patients with low‐risk prostate cancer on active surveillance
por: Tomer, Anirudh, et al.
Publicado: (2020)

Outpatient stereotactic brain biopsies
por: Mathon, Bertrand, et al.
Publicado: (2021)

Magnetic Resonance Imaging–targeted Prostate Biopsy Compared with Systematic Prostate Biopsy in Biopsy-naïve Patients with Suspected Prostate Cancer
por: Alkema, Nicolette G., et al.
Publicado: (2022)

Improving the safety and tolerability of local anaesthetic outpatient transperineal prostate biopsies: A pilot study of the CAMbridge PROstate Biopsy (CAMPROBE) method
por: Thurtle, D, et al.
Publicado: (2018)

The role of music in outpatient prostate biopsy: A comprehensive literature review
por: Belgi, Saniya, et al.
Publicado: (2022)

Rebiopsy rate after transperineal or transrectal prostate biopsy
por: Marenco Jimenez, Jose L., et al.
Publicado: (2021)

The detection and upgrade rates of prostate adenocarcinoma following transperineal template-guided prostate biopsy – a tertiary referral centre experience
por: Muthuveloe, David, et al.
Publicado: (2016)

Gleason grading of prostate cancer in needle core biopsies: a comparison of general and urologic pathologists
por: Al-Maghrabi, Jaudah Ahmed, et al.
Publicado: (2013)

TREXIT: initial experience with transperineal prostate biopsy under local anesthesia in an outpatient setting in South East Asia
por: Yuwono, Arianto, et al.
Publicado: (2021)

Comparison of a Personalized Prostate Biopsy Pattern With Traditional Transrectal Prostate Biopsy: Different Cancer Detection Rate
por: Jiang, Xin, et al.
Publicado: (2022)

Second Reply to Letter to the Editor re: “Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting”
por: White, Jay, et al.
Publicado: (2019)

What is an acceptable false negative rate in the detection of prostate cancer?
por: Verbeek, Jan F. M., et al.
Publicado: (2018)

Updating the Rotterdam Prostate Cancer Risk Calculator with Invasive Cribriform and/or Intraductal Carcinoma for Men with a Prior Negative Biopsy
por: Remmers, Sebastiaan, et al.
Publicado: (2021)

Diagnostic significance of reassessment of prostate biopsy specimens by experienced urological pathologists at a high-volume institution
por: Okubo, Yoichiro, et al.
Publicado: (2022)

Comparison of biopsy under‐sampling and annual progression using hidden markov models to learn from prostate cancer active surveillance studies
por: Li, Weiyu, et al.
Publicado: (2020)

Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting
por: Taira, A V, et al.
Publicado: (2009)

Beyond penile cancer, is there a role for sentinel node biopsy in urological malignancies?
por: Brouwer, O. R., et al.
Publicado: (2016)

The Severity of Pain in Prostate Biopsy Depends on the Biopsy Sector
por: Rempega, Grzegorz, et al.
Publicado: (2023)

Are outpatient transperineal prostate biopsies without antibiotic prophylaxis equivalent to standard transrectal biopsies for patient safety and cancer detection rates?A retrospective cohort study in 222 patients
por: Islam, Majdee, et al.
Publicado: (2021)

Effect of information on prostate biopsy history on biopsy outcomes in the era of MRI-targeted biopsies
por: Lantz, Anna, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7crkoki2rdvi2bnoqt9b97heg3